Charging forward in locally advanced pancreatic cancer
Mené sur 107 patients atteints d'un cancer du pancréas localement avancé, cet essai international multicentrique de phase II évalue l'efficacité, du point de vue du délai avant l'échec du traitement, et la toxicité du nab-paclitaxel en combinaison avec la gemcitabine, en traitement de première ligne
Pancreatic ductal adenocarcinoma is a disease associated with poor prognosis, with more than half of all patients presenting with unresectable locally advanced pancreatic cancer. The natural biology of locally advanced pancreatic cancer does seem distinct from metastatic pancreatic cancer; however, 30–50% of patients with locally advanced pancreatic cancer will develop distant metastasis within 3 months. Initial systemic therapy with FOLFIRINOX (leucovorin, fluorouracil, irinotecan, and oxaliplatin) or nab-paclitaxel plus gemcitabine are recommended for patients with metastatic disease and good performance status; however, these therapies have not been evaluated prospectively in locally advanced pancreatic cancer.
The Lancet Gastroenterology & Hepatology , commentaire, 2019